X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24137) 24137
Publication (4023) 4023
Book Review (2068) 2068
Newspaper Article (212) 212
Book Chapter (57) 57
Conference Proceeding (27) 27
Dissertation (19) 19
Book / eBook (7) 7
Magazine Article (4) 4
Report (3) 3
Data Set (2) 2
Web Resource (2) 2
Government Document (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22129) 22129
humans (16285) 16285
animals (9572) 9572
cell cycle (7211) 7211
cell biology (6110) 6110
mice (6068) 6068
oncology (6031) 6031
female (5790) 5790
cancer (5400) 5400
apoptosis (5149) 5149
proteins (4961) 4961
male (4848) 4848
cyclin-dependent kinases (4807) 4807
biochemistry & molecular biology (4794) 4794
phosphorylation (4715) 4715
expression (4626) 4626
cell line, tumor (4254) 4254
kinases (4215) 4215
gene expression (4081) 4081
cell proliferation (3558) 3558
research (3511) 3511
genetic aspects (2942) 2942
cyclin-dependent kinase inhibitor p21 - metabolism (2822) 2822
middle aged (2803) 2803
signal transduction (2790) 2790
mutation (2754) 2754
cyclin-dependent kinase inhibitor p21 (2668) 2668
cyclin-dependent kinases - metabolism (2542) 2542
tumor suppressor protein p53 - metabolism (2468) 2468
p53 (2431) 2431
tumors (2390) 2390
research article (2300) 2300
analysis (2295) 2295
adult (2281) 2281
article (2256) 2256
multidisciplinary sciences (2252) 2252
aged (2248) 2248
cyclin-dependent kinase inhibitor p16 - genetics (2237) 2237
cyclin-dependent kinase inhibitor p21 - genetics (2231) 2231
cells, cultured (2065) 2065
genes (2026) 2026
immunohistochemistry (1976) 1976
activation (1959) 1959
cell line (1950) 1950
genetics & heredity (1942) 1942
gene expression regulation, neoplastic (1939) 1939
proliferation (1928) 1928
cell growth (1911) 1911
medicine (1858) 1858
cyclin-dependent kinase (1817) 1817
biology (1810) 1810
tumor suppressor protein p53 - genetics (1789) 1789
physiological aspects (1767) 1767
apoptosis - drug effects (1741) 1741
health aspects (1727) 1727
p21 (1713) 1713
cell cycle proteins - metabolism (1691) 1691
cell proliferation - drug effects (1687) 1687
cyclins - metabolism (1686) 1686
protein (1670) 1670
growth (1624) 1624
gene (1610) 1610
cyclin-dependent kinase inhibitor p16 - metabolism (1589) 1589
cells (1585) 1585
cell division (1563) 1563
cell-cycle (1552) 1552
science (1521) 1521
blotting, western (1491) 1491
dna (1491) 1491
gene-expression (1454) 1454
deoxyribonucleic acid--dna (1438) 1438
transfection (1424) 1424
p16 (1410) 1410
protein binding (1410) 1410
molecular sequence data (1408) 1408
rats (1398) 1398
dna damage (1381) 1381
in-vivo (1377) 1377
inhibition (1364) 1364
prognosis (1362) 1362
pathology (1349) 1349
tumor cells, cultured (1345) 1345
cyclin-dependent kinase inhibitor p27 (1331) 1331
down-regulation (1331) 1331
differentiation (1305) 1305
genetics (1290) 1290
cell cycle proteins - genetics (1278) 1278
cyclin-dependent kinases - genetics (1271) 1271
p27 (1266) 1266
cyclins - genetics (1261) 1261
breast cancer (1251) 1251
mice, knockout (1250) 1250
development and progression (1247) 1247
cyclin-dependent kinase inhibitor p27 - metabolism (1242) 1242
dna methylation (1236) 1236
cell cycle - drug effects (1223) 1223
transcription (1219) 1219
care and treatment (1216) 1216
gene expression regulation (1197) 1197
studies (1196) 1196
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24245) 24245
Chinese (95) 95
German (19) 19
Japanese (17) 17
Russian (12) 12
French (3) 3
Portuguese (3) 3
Korean (2) 2
Spanish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 01/2014, Volume 14, Issue 1, pp. 32 - 32
Background: Although MYC is an attractive therapeutic target for breast cancer treatment, it has proven challenging to inhibit MYC directly, and clinically... 
Cyclin-dependent kinase | Breast cancer | Synthetic lethality | MYC | SYNTHETIC LETHAL | C-MYC | TUMOR-CELLS | PROLIFERATION | INHIBITION | GENE | ONCOLOGY | PATHWAY | ESTROGEN | THERAPEUTIC TARGETS | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Cyclin-Dependent Kinase 4 - genetics | Humans | Molecular Targeted Therapy | CDC2 Protein Kinase - metabolism | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | Bcl-2-Like Protein 11 | RNA Interference | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Cell Death - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - metabolism | Cyclin-Dependent Kinase 2 - metabolism | CDC2 Protein Kinase - genetics | CDC2 Protein Kinase - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - genetics | Tumor Suppressor Protein p53 - metabolism | Cyclin-Dependent Kinase 2 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Apoptosis Regulatory Proteins - metabolism | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Line, Tumor | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Care and treatment | Patient outcomes | Cancer cells | Physiological aspects | Genetic aspects | Research | Risk factors | Cyclins | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 06/2017, Volume 8, Issue 1, pp. 15916 - 15916
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen... 
PALBOCICLIB | APOPTOSIS | CELLS | OXIDATIVE STRESS | ADVANCED BREAST-CANCER | MULTIDISCIPLINARY SCIENCES | REGULATES AUTOPHAGY | LETROZOLE | G1 ARREST | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Cyclin-Dependent Kinase 4 - genetics | Humans | Cellular Senescence - drug effects | Cytoplasm - metabolism | Antineoplastic Agents - administration & dosage | Breast Neoplasms - physiopathology | Cyclin E - genetics | Autophagy - drug effects | Breast Neoplasms - metabolism | Female | Cytoplasm - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Mice, Nude | Retinoblastoma Protein - genetics | Cell Line, Tumor | Mice | Cyclin E - metabolism | Cell Cycle - drug effects | Cytoplasm - drug effects | Senescence | Deregulation | Estrogens | Estrogen | Estrogen receptors | Breast cancer | In vitro testing | Autophagy | Machinery | Cyclin-dependent kinase 4 | Inhibitors | Cell cycle | Xenografts | Biomarkers | Breast | Cyclin E | Bioindicators | Inhibition | Phagocytosis | Tumors | Cancer | Index Medicus
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2014, Volume 26, Issue 1, pp. 136 - 149
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have... 
DRUG | INACTIVATION | ADVANCED SOLID TUMORS | MAMMARY-TUMORS | GENE | ONCOLOGY | PATHWAY INHIBITORS | CYCLIN D1 EXPRESSION | GROWTH | PHASE-I | PRECLINICAL EVALUATION | CELL BIOLOGY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Phosphatidylinositol Phosphates - metabolism | Cyclin-Dependent Kinase 4 - genetics | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | MCF-7 Cells | RNA Interference | Time Factors | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - drug effects | Genetic Predisposition to Disease | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Phenotype | Animals | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Signal Transduction - drug effects | Breast Neoplasms - pathology | Mice, Nude | Cell Proliferation - drug effects | Mice | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Medical colleges | Breast cancer | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 9, pp. 2488 - 2499
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet... 
SURVIVAL | PALBOCICLIB | ACTIVATION | ONCOLOGY | PHOSPHORYLATION | SENSITIVITY | LETROZOLE | CELL-CULTURE | COMBINATION | PROTEIN-KINASE B | PACLITAXEL | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Apoptosis - drug effects | Cyclin-Dependent Kinase 4 - genetics | Humans | Indazoles - administration & dosage | Purines - administration & dosage | MCF-7 Cells | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Aminopyridines - administration & dosage | Pyridines - administration & dosage | Receptors, Estrogen - genetics | Pyrimidines - administration & dosage | Cyclin-Dependent Kinase 6 - genetics | Protein-Serine-Threonine Kinases - genetics | Receptors, Estrogen - antagonists & inhibitors | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Proliferation - drug effects | Mice | Drug Resistance, Neoplasm - drug effects | Senescence | Estrogens | Estrogen receptors | AKT protein | Kinases | Cyclin-dependent kinase 4 | Signal transduction | Xenografts | Inhibition | RNA-mediated interference | Cyclin-dependent kinases | Breast cancer | Pharmacology | siRNA | Tumor cell lines | Ribonucleic acid--RNA | Cyclins | 1-Phosphatidylinositol 3-kinase | Cyclin-dependent kinase 2 | Signaling | Sensitivity | Inhibitors | Protein kinase | Cell lines | Breast | Cancer | Apoptosis | Index Medicus | ER+ breast cancer | RNAi screen | CDK4 | cell cycle | PDK1
Journal Article
Oncogene, ISSN 0950-9232, 06/2017, Volume 36, Issue 23, pp. 3334 - 3345
Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational landscape of primary mucosal melanomas (PMM) remains unclear. Forty-six... 
Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Oncogene Proteins, Fusion - metabolism | Skin Neoplasms - drug therapy | Apoptosis - drug effects | Cyclin-Dependent Kinase 4 - genetics | Humans | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | MAP Kinase Kinase 1 - genetics | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacology | Mucous Membrane - drug effects | Tumor Cells, Cultured | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - genetics | MAP Kinase Kinase 1 - metabolism | Cyclin-Dependent Kinase 6 - metabolism | Melanoma - pathology | Transcription Factors - genetics | Cyclin-Dependent Kinase 4 - metabolism | Mucous Membrane - metabolism | Skin Neoplasms - metabolism | Phosphatidylinositol 3-Kinases - genetics | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Mucous Membrane - pathology | Animals | Mice, Nude | Oncogene Proteins, Fusion - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Mitogen-Activated Protein Kinases - metabolism | TARGETED THERAPY | MUTANT MELANOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | IMPROVED SURVIVAL | CANCER | CELL BIOLOGY | MUTATED MELANOMA | GENE FUSIONS | MEK INHIBITION | ONCOLOGY | GENETICS & HEREDITY | RAF INHIBITORS | MUTATIONS | SEQUENCING DATA | Care and treatment | Gene mutations | Melanoma | Development and progression | Cellular signal transduction | Genetic aspects | Health aspects | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2013, Volume 8, Issue 10, pp. e77639 - e77639
Diffuse intrinsic pontine glioma (DIPG) is an incurable tumor that arises in the brainstem of children. To date there is not a single approved drug to... 
INACTIVATION | CELLS | GLIOBLASTOMA | DEPENDENT KINASE 4/6 | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | MUTATION | GROWTH | SENSITIVITY | INTRINSIC PONTINE GLIOMAS | PD 0332991 | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Gamma Rays | Brain Stem Neoplasms - pathology | Cyclin-Dependent Kinase 4 - genetics | Glioma - genetics | Brain Stem Neoplasms - mortality | Glioma - pathology | Glioma - therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Disease Models, Animal | Cyclin-Dependent Kinase Inhibitor p16 - deficiency | Glioma - mortality | Proto-Oncogene Proteins c-sis - genetics | Drug Administration Schedule | Proto-Oncogene Proteins c-sis - metabolism | Signal Transduction | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Piperazines - pharmacology | Animals | Brain Stem Neoplasms - genetics | Cell Cycle Checkpoints - radiation effects | Oncogene Proteins, Fusion - deficiency | Brain Stem Neoplasms - therapy | Cell Cycle Checkpoints - drug effects | Oncogene Proteins, Fusion - genetics | Retinoblastoma Protein - genetics | Survival Analysis | Cell Proliferation - drug effects | Gene Expression Regulation, Neoplastic - radiation effects | Mice | Pyridines - pharmacology | Cell Proliferation - radiation effects | Usage | Gliomas | Genetically modified organisms | Models | Research | Diagnosis | Drug therapy | Cell proliferation | Platelet-derived growth factor | Brain stem | p53 Protein | Brain tumors | Brain cancer | Cyclin-dependent kinases | Radiation | INK4 protein | Radiation therapy | Kinases | Survival | Cyclin-dependent kinase 4 | Cyclins | Radiation dosage | Inhibitors | Glioma | Cell cycle | Genetic engineering | Mutation | Cyclin-dependent kinase inhibitors | Children | Retinoblastoma | Tumors | Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 11/2016, Volume 126, Issue 11, pp. 4076 - 4087
Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is... 
MEDICINE, RESEARCH & EXPERIMENTAL | GASTROINTESTINAL-SYNDROME | APOPTOSIS | STEM-CELLS | REPAIR | DEPENDENT KINASE 4/6 | PUMA | DAMAGE | P21 | DNA-REPLICATION | P53 | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Intestinal Diseases - prevention & control | Cell Cycle - genetics | Stem Cells - immunology | Apoptosis - drug effects | Radiation Injuries, Experimental - immunology | Cyclin-Dependent Kinase 4 - genetics | Apoptosis - genetics | Intestinal Diseases - immunology | Cyclin-Dependent Kinase 6 - immunology | Tumor Suppressor Protein p53 - genetics | Receptors, G-Protein-Coupled - immunology | Radiation Injuries, Experimental - prevention & control | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Cell Cycle - immunology | Tumor Suppressor Proteins - genetics | Apoptosis Regulatory Proteins - genetics | DNA Damage - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Radiation Injuries, Experimental - genetics | Apoptosis Regulatory Proteins - immunology | Cyclin-Dependent Kinase 6 - genetics | Intestinal Diseases - genetics | DNA Damage - immunology | Tumor Suppressor Protein p53 - immunology | Radiation Injuries, Experimental - pathology | Piperazines - pharmacology | Tumor Suppressor Proteins - immunology | Mice, Knockout | Cyclin-Dependent Kinase 4 - immunology | Animals | Apoptosis - immunology | Cyclin-Dependent Kinase Inhibitor p21 - immunology | Stem Cells - pathology | Mice | Pyridines - pharmacology | Receptors, G-Protein-Coupled - genetics | Cell Cycle - drug effects | Usage | Radiotherapy | DNA damage | Analysis | Gastrointestinal system | Colleges & universities | Cell division | FDA approval | Kinases | Gene expression | Experiments | Phase transitions | DNA repair | Proteins | Rodents | Cell cycle | Stem cells | Deoxyribonucleic acid--DNA | Methods | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
by Pek, M and Yatim, S.M.J.M and Chen, Y and Li, J and Gong, M and Jiang, X and Zhang, F and Zheng, J and Wu, X and Yu, Q
Oncogene, ISSN 0950-9232, 08/2017, Volume 36, Issue 35, pp. 4975 - 4986
Therapeutic strategies against KRAS mutant colorectal cancers are developed using cell line models, which do not accurately represent the transcriptome driven... 
BIOCHEMISTRY & MOLECULAR BIOLOGY | PANCREATIC-CANCER | DNA-DAMAGE | TRANSCRIPTION | SYNTHETIC LETHAL INTERACTION | PROLIFERATION | FOXM1 | SUPPRESSION | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | MUTATION STATUS | ONCOLOGY | GENETICS & HEREDITY | CELL-CYCLE | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Diphenylamine - pharmacology | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Cyclin-Dependent Kinase 4 - genetics | Humans | Gene Expression Profiling | Molecular Targeted Therapy | Diphenylamine - analogs & derivatives | Colorectal Neoplasms - drug therapy | Female | Benzamides - pharmacology | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins p21(ras) - metabolism | Colorectal Neoplasms - enzymology | MAP Kinase Kinase Kinases - genetics | HCT116 Cells | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | MAP Kinase Kinase Kinases - metabolism | Random Allocation | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Piperazines - pharmacology | HT29 Cells | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Care and treatment | Research | Gene mutations | Gene expression | Colorectal cancer | Cell cycle | Cell culture | Toxicity | Epithelial cells | Mitosis | Colorectal carcinoma | Cancer therapies | Cyclin-dependent kinase 4 | K-Ras protein | Metastases | Xenografts | Mutation | Colon | Tumors | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2013, Volume 19, Issue 22, pp. 6173 - 6182
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
Cancer Research, ISSN 0008-5472, 10/2009, Volume 69, Issue 19, pp. 7569 - 7576
Journal Article